Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDC20 divergent transcript (CDC20-DT)
- Target
- CDC20-DT
- Molecular classification
- Other (presumed long non-coding RNA or divergent transcript)
01
Overview
The CDC20 divergent transcript (CDC20-DT) is an uncharacterized transcript associated with the CDC20 gene locus. While the canonical CDC20 protein is a mitotic activator of the Anaphase Promoting Complex/Cyclosome (APC/C) and is crucial for cell cycle progression, CDC20-DT refers to an alternative, likely non-protein-coding transcript, with unknown function and no evidence of direct involvement in disease or as a therapeutic target[5]. Most research and drug development in this area targets the CDC20 protein itself, not divergent transcripts.
- Other names
- CDC20 divergent transcriptCDC20-DT
02
Mechanism of action
None. No defined drug mechanisms targeting CDC20-DT.
03
Biological functions
Undefined. There are no well-characterized biological functions for CDC20-DT in scientific literature; functions may be regulatory, but evidence is lacking.
04
Disease associations
None established. No clear involvement in cancer, inflammation, neurodegenerative diseases, or other pathologies is documented for CDC20-DT.
05
Safety considerations
None known. No safety concerns or therapeutic challenges reported.
06
Interacting drugs
None. No drugs are known to selectively or specifically interact with CDC20-DT.
07
Biomarkers
None. CDC20-DT is not recognized as a biomarker for patient selection or efficacy.
Beyond the preview
Go deeper on CDC20 divergent transcript (CDC20-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDC20 divergent transcript (CDC20-DT).